Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.
View Top Employees from Bridge Biotherapeutics, Inc.| Website | http://www.bridgebiorx.com |
| Revenue | $6.7 million |
| Employees | 35 (30 on RocketReach) |
| Founded | 2015 |
| Industry | Biotechnology Research, Manufacturing General, Drug Discovery, Manufacturing, Pharmaceuticals |
| Competitors | AQUALUNG THERAPEUTICS CORPORATION, Allinaire Therapeutics, LLC, KOUTIF THERAPEUTICS, LLC |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Bridge Biotherapeutics, Inc. employee's phone or email?
Bridge Biotherapeutics, Inc. Questions
The Bridge Biotherapeutics, Inc. annual revenue was $6.7 million in 2024.
30 people are employed at Bridge Biotherapeutics, Inc..
Bridge Biotherapeutics, Inc. is based in Seongnam, Kyonggi-do.
The NAICS codes for Bridge Biotherapeutics, Inc. are [3254, 325, 32].
The SIC codes for Bridge Biotherapeutics, Inc. are [283, 28, 80].
Top Bridge Biotherapeutics, Inc. Employees
-
45+
-
View
Toan Nguyen
Director Computational Chemistry and Informatics at Bridge Biotherapeutics, Inc.
Wellesley, MA, US45+ -
1
Related Companies
